Original Research

Identification of inhaler technique errors with a routine procedure in Portuguese community pharmacy

M. Margarida CASTEL-BRANCO, Ana FONTES, Isabel V. FIGUEIREDO

Received (first version): 17-Jul-2017 Accepted: 27-Nov-2017 Published online: 18-Dec-2017

Abstract

Background: A correct selection of drugs prescribed, but also the choice of the appropriate inhaler device, is crucial for the control of respiratory diseases.

Objective: To evaluate the inhaler technique and identify potential errors of patients when treated with inhalers by testing a routine procedure to be implemented in any community pharmacy.

Methods: Adults with asthma/COPD and under inhalation therapy were invited to demonstrate how they use their inhalers. After direct observation it was registered whether all the sequential steps included in the summary of product characteristics (SmPC) were performed.

Results: The study involved 67 patients from 4 community pharmacies (Portugal central region): 34 (50.7%) males, 65.4 (SD=18.28) years old, 42 (62.7%) with COPD, and 23 (34.3%) using more than one inhaler. The 67 patients used 95 inhalers, comprising: 57 (60.0%) multiple dose DPI (dry powder inhalers), 18 (18.9%) single dose DPI, 16 (16.8%) pMDI (pressurized metered dose inhalers), 2 (2.1%) pMDI+spacer and 2 (2.1%) SMI (soft mist inhalers). No errors were made only by 9 (13.4%) patients. In the 75 DPI techniques, the most frequent errors were ‘no previous forced expiration’ (46=61.3%) and ‘no 10s apnea after inhalation’ (51=68.0%); in the 16 pMDIs techniques common errors were ‘lack of hand-lung coordination’ (7=43.8 %), ‘no previous forced exhalation’ (8=50.0%) and ‘no apnea after inhalation’ (10=62.5%). After inhaling from 56 devices containing corticosteroids, 34 (60.7%) of the patients did not wash their mouth.

Conclusion: The study demonstrated the possibility of performing this procedure routinely in Portuguese community pharmacies and also its utility, since 58 (87%) of patients had at least one error during the inhalers use.

Keywords

Asthma; Pulmonary Disease, Chronic Obstructive; Nebulizers and Vaporizers; Pharmacies; Pharmacists; Patient Education as Topic; Quality Assurance, Health Care; Portugal

INTRODUCTION

Inhaled therapy is currently recognized as the first choice in the pharmacological treatment of respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). In fact, the inhalatory route allows the use of lower doses of drugs, a faster onset of action, and less side effects than the systemic (oral or intravenous) administration by placing the drug directly into airways and lungs. Corticosteroids and bronchodilators can be delivered by a wide variety of devices currently on the market, which can be classified into pressurized metered dose inhalers (pMDI), dry powder inhalers (DPI) and soft mist inhalers (SMI).

The deposition of the inhaled drug in the lung is dependent on particle size, inhalation technique, and type of inhaler device used. The complex interaction among these factors results in the need for different inhalation techniques for each type of inhaler. It is crucial to ensure that the choice of the inhaler is adjusted to each patient. For example, patients using pMDIs need to coordinate the activation of the device and the inspiratory effort, inhaling slowly and deeply; however, the DPIs only require a fast inspiratory flow rate. The association of a spacer to pMDIs allows the patient to perform multiple inhalations at tidal volume without the need for prior forced expiration and apnea after inhalation, and the synchronization problem with pMDIs disappears.

Therefore, in addition to the appropriate choice of pharmacological therapy, it will be essential for a good control of respiratory diseases, to correctly use the inhaler devices. Only by ensuring adequate lung deposition of drug particles, it will be possible to maximize the benefits of treatment and to minimize potential adverse effects. However, incorrect use of inhalers remains an obstacle in the management of respiratory disorders. A systematic review of the literature confirmed that a large number of patients make errors in the use of their inhalers, this number may reach 94% of users, depending on the type of inhaler and on the evaluation method used.

International guidelines recommend the optimization of the inhaled therapy follow-up of patients by healthcare professionals by means of a periodic review of the inhalation technique. In fact, when an inhaled therapy is prescribed for the first time, teaching the patient how to use the device correctly is advised. However, much of the information may get lost during the complicated hospital discharge or in the first medical consultation when the patient returns home.
TABLE 1. Sample characteristics.

| Gender     | n (%) |
|------------|-------|
| Male       | 34 (50.7) |
| Female     | 33 (49.3) |

| Age (years) | n (%) |
|-------------|-------|
| 18-24       | 3 (4.5) |
| 25-44       | 8 (11.9) |
| 45-64       | 14 (20.9) |
| 65-74       | 17 (25.4) |
| 75 and over | 25 (37.3) |

| Disease     | n (%) |
|-------------|-------|
| Asthma      | 25 (37.3) |
| COPD        | 42 (62.7) |

| Number of inhalers | n (%) |
|--------------------|-------|
| 1                  | 44 (65.7) |
| 2                  | 19 (28.4) |
| 3                  | 3 (4.5) |
| 4                  | 1 (1.5) |

| Types of inhaler | n (%) |
|------------------|-------|
| 1                | 47 (70.1) |
| 2                | 18 (26.9) |
| 3                | 2 (3.0) |

Table 2. Relative frequencies of all types of inhaler devices presented on the 95 evaluated inhalation techniques.

| Inhaler Devices | n (%) |
|-----------------|-------|
| pMDI            | 16 (16.8%) |
| pMDI-spacer     | 2 (2.1%) |
| SMI             | 2 (2.1%) |
| DPI             | 2 (2.1%) |
| Aerolizer       | 6 (6.3%) |
| Breezhaler®     | 8 (8.4%) |
| Handihaler®     | 4 (4.2%) |
| Diskus®         | 32 (33.7%) |
| Ellipta®        | 2 (2.1%) |
| Genuair®        | 2 (2.1%) |
| Novolizer®      | 1 (1.1%) |
| Spironax®       | 1 (1.1%) |
| Turbohaler®     | 19 (20.0%) |
| DPI - Dry Powder Inhaler; pMDI - pressurized Metered Dose Inhaler; SMI - Soft Mist Inhaler |

Community pharmacists are in an excellent position to continuously educate patients on the use of inhalers. A patients first visit to the pharmacy represents the time for the patient to independently learn how to manage the inhaler, so the educational intervention at this moment is highly important.8,9 Many studies have been published focusing on the incorrect use of inhaler devices, but few refer to the possibility of such assessments to be done routinely in a community pharmacy.8,10,11 To our knowledge, nothing has been published in Portugal in this area. Thus, the aim of this study was to evaluate the inhaler technique and identify potential errors of patients treated with inhalers, by testing a routine procedure to be implemented in community pharmacies.

METHODS

The study was approved by the Ethics Committee of Coimbra University (EC-017/2014). The study took place between 1st February and 31st May 2015 in four pharmacies in the Central Region of Portugal. Advertisement posters were displayed in participant pharmacies to inform respiratory disease patients of the need for a periodic review of their inhalation technique. Portuguese speaking patients with asthma or COPD, and with instituted inhaled therapy, were invited to participate when they came to pick their prescriptions or when they asked about the posters. Exclusion criteria included a) younger than 18 years patients, b) inhaled therapy first time users, c) inhalers used for respiratory disorders other than asthma or COPD, and d) any obvious signs of cognitive impairment. All individuals who showed interest and who fulfilled the inclusion criteria signed a consent form to participate in the study.

The study consisted of asking participants to demonstrate how they normally used their inhalers. In a private counselling room, participants were asked to perform the inhalation technique with their own inhaler(s) or with an identical device containing placebo. Specific checklists for each type of device were prepared with information obtained from inhalers’ official summaries of product characteristics (SmPCs). When several medicines with identical device existed, the information contained in their SmPCs was compiled and a unique checklist was created for all of them. Each checklist comprised a series of steps that should be sequentially executed. A community pharmacist member of the research team, specifically trained in the use of these checklists, recorded if the patient correctly performed each of the steps included in the checklists.

Descriptive statistics with absolute and relative frequencies of errors identified for each of the steps in each checklist were performed. Percentage of errors per technique was calculated taking into consideration the number of steps required for each device.

RESULTS

The study involved a total of 67 patients whose characteristics are presented in Table 1. Patients aged between 18 and 93 years old. It was counted more than an inhaler in 23 (34.3%) patients and more than one type of inhaler in 20 (29.8%) of these patients. In total 57 (60.0%) of the patients. In total 95 inhalation techniques were evaluated: 57 (60.0%) with multiple dose DPI, 18 (18.9%) with single dose DPI, 16 (16.8%) with pMDI, 2 (2.1%) with pMDI with a spacer and 2 (2.1%) with SMI (Table 2). In the 95 inhalation techniques evaluated, 17 (17.9%) involved relief medication (12 (12.6%) with pMDI, 2 (2.1%) with spacer in combination with a pMDI and 3 (3.2%) with Turbohaler DPI (also called Turbuhaler in other countries). Each evaluation procedure took between 5 and 10 minutes

Table 3 shows the errors identified for the different categories of inhaler devices (DPIs, pMDIs and SMI) in the total evaluated inhalation techniques. No errors were made by 9 (13.4%) patients. It was also found that in 34 of the 56 (60.7%) inhalation techniques in which there was administration of corticosteroids, patients did not wash the oral cavity after inhalation, as recommended with this type of drug.
DISCUSSION

The results obtained in this study reveal that not only it is possible to use a routine procedure in Portuguese community pharmacies to check the inhalation techniques performed by patients but is also advisable, since 87% of participants had at least one error in the execution of their inhalation technique. Several studies have demonstrated the added value of the community pharmacist intervention in affecting respiratory diseases, particularly among asthmatic patients. The published studies refer complex interventions focused either on knowledge regarding the disease and beliefs about medication or on the use of such medication and treatment adherence, evaluating repercussions in terms of clinical, economic and humanistic outcomes.12-17

Considering that incorrect inhalation technique is often the main obstacle to successfully treat patients with asthma or COPD,13,14 our study sought to test a service to assess the inhalation technique in patients using inhaler devices, and the feasibility to be implemented in the routine of a Portuguese community pharmacy. Each intervention took between 5 and 10 minutes, proving to be compatible with the daily commitments of dispensing in a community pharmacy. This fact had already been approached by Basueti et al. in Australian pharmacies with assistance of about 2.5 min/patient,8 by Hämmerlein et al. in community German pharmacies with assistance from about 15 min/patient and by García-Cárdenas et al. in Spanish community pharmacies.9 Extending this service to all community pharmacies in Portugal would facilitate overcoming the incorrect use of inhalers, increasing the chances of a correct control of respiratory diseases. Additionally, this simple procedure would also allow periodic patient monitor over the time, preventing possible deviations resulting from the routine use and loose of attention with the device.8 According to Asthma19 or COPD10 international guidelines, before modifying the prescription of pharmacological therapy the inhalation technique should be assessed and eventual errors corrected.

Community pharmacist could be an ideal professional to perform this assessment in a routinary basis. Since 2005 Denmark is an example of the implementation of an inhaler technique assessment in community pharmacies, officially funded, the "Inhaler Technique Assessment Service (ITAS)". However Kae & Sporrong recently explored the reasons why users join or not to this service, and they found that the vast majority of users do not feel the need for this service and will adhere only if persuaded to do so.21 Interestingly, the literature reveals that between 50% and 80% or more of patients had at least one error in their inhalation technique,11,16, which was higher in our study (87%). Further studies should focus on assessing the reasons why patients do not sufficiently value these services and what should pharmacists do to improve their acceptance.

The use of any inhaler involves performing a series of steps correctly and in the proper order. If the patient makes errors, the amount of drug that reaches his lungs will be significantly reduced and thus he will be unable to control his respiratory disorder.6,8 In the present study, pMDIs were associated with a higher percentage of errors than DPIs (26.6% and 18.2%, respectively, taking into account both the number of inhalation techniques carried out and the number of steps of each one). An observational study to evaluate the inhalation technique in patients with asthma and COPD performed by Arora et al. in New Delhi also found that 82.3% of 300 patients included in the study made errors, and 94.3% and 82.3% of patients with pMDI and DPIs respectively, held at least one error.18 These results are the consequence of the most predictable difficulty in the use of pMDIs, which requires a good ability of hand-lung coordination, compared to the use of DPIs, not requiring this ability of coordination by the patient.6,12,23

García-Cárdenas et al. specifically explored the Turbobalher device in a Spanish population of asthma patients and found that 47.0% of patients using Turbobalher did not exhale before inhalation and 42.5% did not hold their breath then for 8 seconds.9 The errors in our study are coincident with these and are common to all types of devices, namely, not exhaling to residual lung capacity before inhalation (73.3% - 55/75) and not suspending breathing for 10 seconds after inhalation (84.0%). These errors are also referred as the most common by Lavorini et al. on a systematic review of the topic.6 In a study by Hämmerlein et al. involving 597 patients at 55 community pharmacies in Germany, the most common error detected, albeit at a lower percentage, was not to suspend breath for 5-10 seconds after inhalation (35.8%).10 However the results obtained in our study – nearly 70% for not breath holding after inhalation may be overstated because an

Table 3. Errors identified in all inhalation techniques (n=95).

| Error (n (%) | DPI (n=75) | pMDI (n=16) | pMDI-spacer (n=2) | SMI (n=2) |
|-------------|------------|-------------|------------------|-----------|
| Failure to pierce capsule (n=18) | 3 (16.7%) | - | - | - |
| Error in dose activation with multiple dose DPI (n=57) | 8 (14.0%) | - | - | - |
| Not breathing out gently away before inhalation | 46 (61.3%) | 8 (50.0%) | - | 1 (50.0%) |
| Inhalation too slow | 25 (33.3%) | - | - | - |
| Not holding breath for about 10 seconds after inhalation | 51 (68.0%) | 10 (62.5%) | - | 2 (100.0%) |
| Not replacing the cap after inhalation (n=57) | 2 (3.3%) | - | - | - |
| Not shaking the device before inhalation | - | 6 (37.5%) | 0 (0.0%) | - |
| Failure to make tight seal with lips | - | 3 (18.8%) | - | - |
| Failure to synchronize inhalation with device actuation | - | 7 (43.8%) | - | - |
| Not use mask or mouthpiece well adapted | - | - | 0 (0.0%) | - |
| Not perform 10 inhalations in tidal volume | - | - | 0 (0.0%) | - |
| Not properly rotating the transparent base with SMI | - | - | - | 1 (50.0%) |
| Not pressing the dose release button with SMI | - | - | - | 1 (50.0%) |
| No errors | 13 (17.3%) | 1 (6.3%) | 2 (100.0%) | 0 (0.0%) |

DPI - Dry Powder Inhaler; pMDI - pressurized Metered Dose Inhaler; SMI - Soft Mist Inhaler.
apneic period of 10 seconds was considered, instead of 5-10 seconds.8,9

In the present study, 61.1% of patients receiving inhaled corticosteroids did not wash their mouth after inhalation as recommended in order to avoid the deposition of the corticosteroid at the level of the oropharynx with consequent risk of adverse effects such as candidiasis, cough or dysphonia.4 In the study of García-Cárdenas et al. 42.8% of patients did not rinse their mouths with water after inhalation.7

Another error often detected was inhaling with an inappropriate speed for the type of device. Thus, contrary to what is desirable, in our study there was a rapid inhalation with pMDIs in 42.9% of patients and a slow inhalation with DPIs in 34.7% of patients. García-Cárdenas et al. reported that 21.5% of 367 asthma patients involved in a study evaluating the inhalation technique with Turbohaler did not inhale quickly and vigorously as recommended.5 In turn, Hämmerlein et al. recorded an inhalational flow inadequate in only 17.8% of patients.10

Though the present study has focused only on the possibility of implementing a routine procedure for evaluation and possible correction of the inhalation technique in users of Portuguese community pharmacies, some studies demonstrated the added value of pharmacists’ intervention on the quality of inhalation technique, confirming the need for reevaluation and reeducation of patients about their inhalation technique regularly over the course of therapy.7,8,10 These services are not currently reimbursed in Portugal, but studies like the present might open the room for claiming for payment.

The main limitation of the study was the small number of participants (n=67), resulting from the short time of the study and the involvement of only 4 pharmacies. Another limitation was the restriction to a small geographic area, in the Center of Portugal region, which prevents generalization of the results to the rest of the country.

CONCLUSIONS

This study tested a routine procedure for verification of the inhalation techniques performed by patients in real life in Portuguese community pharmacies. The study allowed the rapid identification of errors in order to its immediate correction. The results confirm that it is feasible to use this routine procedure in a community pharmacy, but also that is a necessary procedure because 87% of participants exhibited at least one error in the execution of their inhalation technique. Participation of the community pharmacists should not be limited to identifying the inhalation technique errors, but to educate the patient to correct them. Future studies should assess the efficacy of the pharmacists in this goal.

CONFLICT OF INTEREST

None.

FUNDING

None.

References

1. Dekhuijzen PN, Vincken W, Virchow JC, Roche N, Agusti A, Lavorini F, van Aalderen WM, Price D. Prescription of inhalers in asthma and COPD: Towards a rational, rapid and effective approach. Respir Med. 2013;107(12):1817-1821. doi: 10.1016/j.rmed.2013.09.013
2. Newman SP. Inhaler treatment options in COPD. Eur Respir Rev. 2005;14(96):102-108. doi: 10.1183/09059180.05.0009605
3. Capstick TG, Clifton IJ. Inhaler technique and training in people with chronic obstructive pulmonary disease and asthma. Expert Rev Respir. 2012;6(1):91-101. doi: 10.1586/ers.11.89
4. Cordeiro M. [Inhalatory therapy: Principles, Inhalation Technique and inhalers]. Loures: Lusodidacta, 2014.
5. Chorão P, Pereira AM, Fonseca JA. Inhaler devices in asthma and COPD - an assessment of inhaler technique and patient preferences. Respir Med. 2014;108(7):968-975. doi: 10.1016/j.rmed.2014.04.019
6. Lavorini F, Magnan A, Dubus JC, Voshaar T, Corbeta L, Broeders M, Dekhuijzen R, Sanchis J, Viejo JL, Barnes P, Corrigan C, Levy M, Crompton GK. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102(4):593-604. doi: 10.1016/j.rmed.2007.11.003
7. Bouwmeester C, Kraft J, Bungay KM. Optimizing inhaler use by pharmacist-provided education to community-dwelling elderly. Respir Med. 2015;109(10):1363-1368. doi: 10.1016/j.rmed.2015.07.013
8. Bashieti IA, Reddel HK, Armour CL, Bosnic-Anticevic SZ. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J Allergy Clin Immunol. 2007;119(6):1537-1538. doi: 10.1016/j.jaci.2007.02.037
9. García-Cárdenas V, Sabater-Hernández D, García-Corbas JP, Faus MJ, Martinez-Martinez F, Benrimoj SI. Errors in Turbohaler technique in a Spanish population of asthmatic patients. Respir Care. 2012;57(5):817-818. doi: 10.4187/rescare.01757
10. Hämmerlein A, Müller U, Schulz M. Pharmacist-led intervention study to improve inhalation technique in asthma and COPD patients. J Eval Clin Pract. 2011;17(1):51-70. doi: 10.1111/j.1365-2753.2010.01369.x
11. Farabaugh M, McMillan A, Garofoli G. Assessment of asthma inhaler technique in two community pharmacies. Inov Pharm. 2014;5(3):171.
12. Schulz M, Verheyen F, Mühlig S, Müller JM, Mühlbauer K, Knoop-Schnickert E, Petermann F, Bergmann KC. Pharmaceutical care services for asthma patients: a controlled intervention study. J Clin Pharmacol. 2001;41(6):668-676. Doi: 10.1177/002237020122010438
13. Saini B, Kass I, Armour C. Development, implementation, and evaluation of a community pharmacy – based asthma care model. Ann Pharmacother. 2004;38(11):1954-1960. doi: 10.1345/aph.1E045
14 Mangiapane S, Schulz M, Mühlig S, Ihle P, Schubert I, Waldmann HC. Community pharmacy – based pharmaceutical care for asthma patients. Ann Pharmacother. 2005;39(11):1817-1822. doi: 10.1345/aph.1G180

15 Mehuys E, Van Bortel L, De Bolle L, Van Tongelen I, Annemans L, Remon JP, Brusselle G. Effectiveness of pharmacist intervention for asthma control improvement. Eur Respir J. 2008;31(4):790-799. doi: 10.1183/09031936.00112007

16 Armour CL, Reddel HK, LeMay KS, Saini B, Smith LD, Bosnic-Anticevich SZ, Song YJ, Alles MC, Burton DL, Emmerton L, Stewart K, Krass I. Feasibility and effectiveness of an evidence-based asthma service in Australian community pharmacies: a pragmatic cluster randomized trial. J Asthma. 2013;50(3):302-309. doi: 10.3109/02770903.2012.754463

17 García-Cárdenas V, Sabater-Hernández D, Kenny P, Martínez-Martínez F, Faus MJ, Benrimoj SI. Effect of a pharmacist intervention on asthma control. A cluster randomised trial. Respir Med. 2013;107(9):1346-1355. doi: 10.1016/j.rmed.2013.05.014

18 Arora P, Kumar L, Vohra V, Sarin R, Jaiswal A, Puri MM, Rathee D, Chakraborty P. Evaluating the technique of using inhalation device in COPD and bronchial asthma patients. Respir Med. 2014;108(7):992-998. doi: 10.1016/j.rmed.2014.04.021

19 Global Initiative for Asthma (GINA). 2015. Available from: http://www.ginasthma.org/ (accessed 16 July 2017).

20 Global Initiative for Chronic Obstructive Lung Disease (GOLD). 2015. Available from: http://www.goldcopd.org/ (accessed 16 July 2017).

21 Kaae S, Sporrong SK. Patients' reasons for accepting a free community pharmacy asthma service. Int J Clin Pharm. 2015;37(5):917-924. doi: 10.1007/s11096-015-0142-z

22 Al-Showair RA, Tarsin WY, Assi KH, Pearson SB, Chrystyn H. Can all patients with COPD use the correct inhalation flow with all inhalers and does training help? Respir Med. 2007;101(11):2395-2401. doi: 10.1016/j.rmed.2007.06.008

23 Chrystyn H, Price D. Not all asthma inhalers are the same: factors to consider when prescribing an inhaler. Prim Care Respir J. 2009;18(4):243-249. doi: 10.4104/pcrj.2009.00029